10 completed, 3 withdrawn, 2 recruiting, 2 terminated. 11 Phase 2, 9 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Recurrent Fallopian Tube Cancer: new trials by email Literature Review of Recurrent Fallopian Tube Cancer trials Research Report on Recurrent Fallopian Tube Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Reirradiation, Total Ablative Strategy - Recurrent Gynecologic Cancer, Recurrent Uterine Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-06-11 | 2026-10-16 | |
| Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Niraparib, Dostarlimab - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Withdrawn | AGO Research GmbH | 2023-11-01 | 2025-04-06 | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Oregovomab, Niraparib - Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary | Phase 2 | Active not recruiting | CanariaBio Inc. | 10 | 2022-07-25 | 2026-04-03 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers Ubamatamab, Cemiplimab, Sarilumab - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 890 | 2018-05-21 | 2026-09-25 |
| Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360) - Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1 / Phase 2 | Unknown | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 85 | 2016-04-01 | 2021-06-18 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 | |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer mifepristone, carboplatin, gemcitabine hydrochloride - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Chicago | 31 | 2013-11-01 | 2018-09-11 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer paclitaxel, ganetespib, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 12 | 2013-10-09 | 2024-03-26 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Tivozanib - Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Completed | Northwestern University | 31 | 2013-06-06 | 2021-10-12 |
| Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer auranofin, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Early Phase 1 | Completed | Mayo Clinic | 10 | 2012-11-02 | 2019-08-02 |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 7 | 2012-08-20 | 2020-03-27 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride - Leydig Cell Tumor, Ovarian Sarcoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 12 | 2012-05-01 | 2015-08-04 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer questionnaire administration, quality-of-life assessment, psychosocial assessment and care - Anxiety Disorder, Depression | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 39 | 2010-10-01 | 2015-10-09 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin SJG-136, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 19 | 2010-07-01 | 2015-05-25 |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2009-04-01 | 2022-08-01 |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer sunitinib malate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2007-01-01 | 2015-01-27 |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer cediranib maleate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2006-04-01 | 2018-08-29 |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, carboplatin, paclitaxel - Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2019-02-20 |
Fallopian Tube Neoplasms (19) · Carcinoma, Ovarian Epithelial (16) · Ovarian Neoplasms (4) · Endometrial Neoplasms (3) · Uterine Cervical Neoplasms (3) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Breast Neoplasms (2) · Leydig Cell Tumor (2) · Neoplasms (2) · Pseudomyxoma Peritonei (2) · Recurrence (2) · Anxiety Disorders (1) · Breast Neoplasms, Male (1) · Brenner Tumor (1)
Adnexal Diseases (19) · Endocrine Gland Neoplasms (19) · Endocrine System Diseases (19) · Fallopian Tube Diseases (19) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Genital Diseases (19) · Genital Diseases, Female (19) · Genital Neoplasms, Female (19) · Gonadal Disorders (19) · Neoplasms by Site (19) · Ovarian Diseases (19) · Urogenital Diseases (19) · Urogenital Neoplasms (19) · Neoplasms (17)
Carboplatin (3) · Gemcitabine (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Metformin (2) · Paclitaxel (2) · Taxes (2) · epacadostat (2) · niraparib (2) · sargramostim (2) · 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · Auranofin (1) · Behavior Therapy (1) · Biosimilar Pharmaceuticals (1) · Chromatography, Liquid (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (3) · Fox Chase Cancer Center (2) · University of Chicago (2) · AGO Research GmbH (1) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (1) · CanariaBio Inc. (1) · Case Comprehensive Cancer Center (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) · Mayo Clinic (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Regeneron Pharmaceuticals (1)
United States (15) · Canada (3) · Australia (1) · Belgium (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Kunle Odunsi (3) · Aminah Jatoi, M.D. (1) · Angela Jain (1) · Barbara Andersen, PhD (1) · Daniela Matei, MD (1) · Gina Martina-Smaldone, MD (1) · Holger Hirte (1) · James Biagi (1) · Marta Crispens (1) · Rita Nanda (1) · Seiko Yamada (1) · Steven Waggoner, MD (1) · Sunil Gupta, MD, FRCPC (1)
PMID 25895616, PMID 35254001, PMID 39652449, PMID 40132910
P30CA006927 (2), 2019 (1), N01CM00100 (1), N01CM62201 (1), N01CM62203 (1), N01CM62209 (1), P30CA014599 (1), P30CA016056 (1), R21CA135005 (1)